#USA #Dallas #ITF Therapeutics #DUVYZAT #Duchenne

ITF Therapeutics to Showcase Research at 2025 MDA Conference

ITF Therapeutics LLC, a prominent player in the pharmaceutical sector and the U.S. affiliate of Italfarmaco, has made significant strides in the treatment of Duchenne muscular dystrophy (DMD) with its latest product DUVYZAT™ (givinostat). The company recently announced that seven abstracts have been accepted for presentation at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, scheduled for March 16-19, 2025, in Dallas, Texas.

Key Research Highlights

The presentations from ITF Therapeutics will focus on various aspects of the long-term safety and efficacy of givinostat in DMD patients. Specifically, the data will address:

• - Long-term safety of givinostat through an open-label extension study
• - The impact on respiratory function in patients pre- and post-ambulation loss
• - A comparison of disease progression models between standard care and givinostat treatment
• - Insights from an observational study examining real-world outcomes for patients undergoing treatment with givinostat

This research is crucial as it provides the Duchenne community with updated and robust data, further affirming the role of givinostat in managing DMD.

Experiences from the Previous Year

Reflecting on the previous year’s MDA conference, where ITF Therapeutics marked its first appearance, company president Matt Trudeau expressed the value of engaging with the Duchenne community. This experience has influenced their commercialization strategy, leading to increased patient access to DUVYZAT shortly after its FDA approval.

"In 2024, we attended our first MDA Clinical and Scientific Conference to listen to the Duchenne community and learn about their unique needs and goals as we prepared for the U.S. FDA approval of DUVYZAT for the treatment of DMD," Trudeau said. His insights into the community's needs have been integral in promoting access to treatment for hundreds of patients since then.

Details on Presentations

Here are a few notable abstracts along with their respective presenters:

• - Givinostat Efficacy in Duchenne Muscular Dystrophy Natural History Comparison Applying Propensity Score Matching

Presenter: David Gómez Andrés, Pediatric Neurologist
Poster Number: P87

• - Givinostat Effect on Respiratory Function in Duchenne Muscular Dystrophy Before and After Ambulation Loss Results from EPIDYS, OLE, and PRO-DMD-01

Presenter: Craig M. McDonald, M.D., Chair, Department of Physical Medicine, UC Davis Health
Poster Number: P80

• - Long-term Safety of Givinostat in Patients with Duchenne Muscular Dystrophy Results From an Open-label Extension Study

Presenter: John F. Brandsema, M.D., Pediatric Neurologist
Poster Number: P275

Support for Community Engagement

In addition to the poster presentations, ITF Therapeutics will sponsor two notable events during the MDA conference:

Neuromuscular Advocacy Collaborative Meeting

Date: Sunday, March 16, 2025, 2:00-5:00 p.m. CST
This event invites advocacy partners to reflect on the achievements from 2024 and strategize future collaborations.

Industry Forum Breakfast

Date: Monday, March 17, 2025, 7:00-8:00 a.m. CST
Presenters will delve into the critical role of histone deacetylase (HDAC) inhibition in the management of DMD.

About DUVYZAT™

DUVYZAT has gained FDA approval as a histone deacetylase inhibitor for treating DMD in patients aged 6 and older. This therapeutic intervenes by moderating the overactive HDAC enzymes associated with chronic muscle inflammation and repair failure in DMD patients.

The Role of ITF Therapeutics

Established in January 2024, ITF Therapeutics is dedicated to developing and commercializing products for rare diseases. By aligning closely with patient advocacy groups and ensuring that the needs of the DMD community are met, ITF Therapeutics underscores its commitment to improving the lives of patients and their families.

For more information, please visit DUVYZAT’s website or ITF Therapeutics’ website.